“Roberto Cosimo Melcangi, Ph.D. at UniMi’s Department of Pharmacological and Biomolecular Sciences, led a team of 10 researchers from six institutions who performed methylation analysis in blood samples of 16 PFS patients and 20 healthy control-group patients, and in cerebrospinal fluid (CSF) samples of 16 PFS patients and 13 controls. “For the first time, we demonstrate a tissue-specific methylation pattern of SRD5A2 promoter in PFS patients,” writes Prof. Melcangi. He concludes that methylation of the SRD5A2 promoter in PFS patients “could represent an important mechanism of neuroactive steroid levels and behavioral disturbances previously described in PFS.”
This is a three-year study, in which 16 men with PFS and 25 control patients were evaluated, also uncovered evidence of neuropathy of the pudendal nerve among those with severe erectile dysfunction. More date needs to be gathered before drawing conclusions on what appears to be a non-statistical valid study.